UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/15.01.25 | Real-time BOERSE MUENCHEN 05:40:24 2024-07-12 am EDT | ||
| 3.7 EUR | 0.00% |
|
| Current month | +25.00% | ||
| 1 month | -2.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 3.7 | 0.00% |
| 24-07-11 | 3.7 | +1.37% |
| 24-07-10 | 3.65 | +1.67% |
| 24-07-09 | 3.59 | +8.46% |
| 24-07-08 | 3.31 | +11.45% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 05:40 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC5VER |
| ISIN | DE000HC5VER9 |
| Date issued | 2023-04-11 |
| Strike | 500 $ |
| Maturity | 2025-01-15 (188 Days) |
| Parity | 10 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.24 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.11 € |
| Spread % | 2.89% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Warrants
- Warrant